{"id":130490,"date":"2024-08-07T14:44:29","date_gmt":"2024-08-07T09:14:29","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=130490"},"modified":"2024-08-07T15:25:00","modified_gmt":"2024-08-07T09:55:00","slug":"smallcap-stock-jumps-8-after-completing-phase-1-clinical-trial-for-its-drug","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/smallcap-stock-jumps-8-after-completing-phase-1-clinical-trial-for-its-drug\/","title":{"rendered":"Smallcap stock jumps 8% after completing phase 1 clinical trial for its drug"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-3132771867\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>The shares of the generic pharmaceutical products manufacturer gained up to 8 percent after the company reached a significant milestone by completing Phase 1 Clinical Trial for Recombinant Human Albumin (rHA).&nbsp;<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-806192029\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><p><strong>Shilpa Medicare Ltd<\/strong> has a market capitalization of Rs 6,950.49 crore, the shares were trading at Rs 708.70 per share, increasing around 7 percent as compared to the previous closing price of Rs 665.85 apiece.\u00a0<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Reason for Rise:-&nbsp;<\/strong><\/h2><p>According to the company filing, Shilpa Medicare Ltd announces the successful completion of its Phase 1 clinical trial for recombinant human albumin 20% (rHA). The positive results from this trial mark a significant milestone in the development of rHA, demonstrating its potential as a viable alternative to plasma-derived human serum albumin.&nbsp;<\/p><p>Moreover, after the success of Phase 1, the company is advancing rHA to Phase 3 clinical trials. SML expects to commence the Phase 3 clinical trials by Q4 of FY25 and the trials are likely to be completed over the next 9 to 12 months post-commencement. Filing for product approval in various geographies is expected to commence in FY26.&nbsp;<\/p><div class=\"trade-content_5\" id=\"trade-2034941292\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Financial condition:-&nbsp;<\/strong><\/h2><p>Looking into the company&#8217;s finances, Shilpa Medicare Ltd.&#8217;s revenue increased by 9 percent from Rs 264 Crore in Q4FY23 to 292 Crore in Q4FY24. During the same period, net profits increased from a loss of Rs 8 crore to a profit of Rs 24 crore.&nbsp;<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Remarkable return:-&nbsp;<\/strong><\/h2><p>The stock has given a return of 82.09 percent in the last six months and a multi-bagger return of 121.57 percent this year. If an individual invested Rs 1 lakh eight months ago, it would be worth now Rs 2.21 lakh.&nbsp;<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Ratio analysis:-&nbsp;<\/strong><\/h2><p>Examining the company\u2019s crucial ratio, return on equity inclined from (1.82) percent in FY22-23 to 1.76 percent in FY23-24, while during the same time frame return on capital employed also inclined from 1.14 percent to 6.03 percent. In contrast, the net profit margin (NPM) stands at 3.18 percent in fiscal year 22-23.&nbsp;<\/p><h2 class=\"wp-block-heading\"><strong>Company profile:-&nbsp;<\/strong><\/h2><p>Shilpa Medicare Limited develops, manufactures, and sells cancer medications and formulations. The company offers a variety of goods, including APIs, formulations, biosimilars, ophthalmic and oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales, and transdermal patches.<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Written by:- Abhishek Singh&nbsp;<\/strong><\/p><\/blockquote><h4 class=\"wp-block-heading\" id=\"h-disclaimer\"><strong>Disclaimer<\/strong><\/h4><div class=\"wp-block-image\"><figure class=\"aligncenter size-medium\"><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer-300x300.png\" alt=\"\" class=\"wp-image-26306\"\/><\/figure><\/div><p><strong>The views and investment tips expressed by investment experts\/broking houses\/rating agencies on <a href=\"http:\/\/tradebrains.in\/\">tradebrains.in<\/a> are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing<\/strong>.<\/p><div class=\"trade-after-content\" id=\"trade-3299819517\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>The shares of the generic pharmaceutical products manufacturer gained up to 8 percent after the company reached a significant milestone by completing Phase 1 Clinical Trial for Recombinant Human Albumin (rHA).&nbsp; Shilpa Medicare Ltd has a market capitalization of Rs 6,950.49 crore, the shares were trading at Rs 708.70 per share, increasing around 7 percent [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":98971,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[4865,31,13525],"tags":[],"class_list":["post-130490","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-analysis","category-news","category-stock-updates"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Smallcap stock jumps 8% after completing phase 1 clinical trial for its drug - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"The shares of the generic pharmaceutical products manufacturer gained up to 8 percent after the company reached a significant milestone by completing Phase 1 Clinical Trial for Recombinant Human Albumin (rHA).\u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/smallcap-stock-jumps-8-after-completing-phase-1-clinical-trial-for-its-drug\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Smallcap stock jumps 8% after completing phase 1 clinical trial for its drug\" \/>\n<meta property=\"og:description\" content=\"The shares of the generic pharmaceutical products manufacturer gained up to 8 percent after the company reached a significant milestone by completing Phase 1 Clinical Trial for Recombinant Human Albumin (rHA).\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/smallcap-stock-jumps-8-after-completing-phase-1-clinical-trial-for-its-drug\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-07T09:14:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-07T09:55:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/smallcap-stock-jumps-8-after-completing-phase-1-clinical-trial-for-its-drug\/\",\"url\":\"https:\/\/tradebrains.in\/features\/smallcap-stock-jumps-8-after-completing-phase-1-clinical-trial-for-its-drug\/\",\"name\":\"Smallcap stock jumps 8% after completing phase 1 clinical trial for its drug - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/smallcap-stock-jumps-8-after-completing-phase-1-clinical-trial-for-its-drug\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/smallcap-stock-jumps-8-after-completing-phase-1-clinical-trial-for-its-drug\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\",\"datePublished\":\"2024-08-07T09:14:29+00:00\",\"dateModified\":\"2024-08-07T09:55:00+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"The shares of the generic pharmaceutical products manufacturer gained up to 8 percent after the company reached a significant milestone by completing Phase 1 Clinical Trial for Recombinant Human Albumin (rHA).\u00a0\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/smallcap-stock-jumps-8-after-completing-phase-1-clinical-trial-for-its-drug\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/smallcap-stock-jumps-8-after-completing-phase-1-clinical-trial-for-its-drug\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/smallcap-stock-jumps-8-after-completing-phase-1-clinical-trial-for-its-drug\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/smallcap-stock-jumps-8-after-completing-phase-1-clinical-trial-for-its-drug\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Smallcap stock jumps 8% after completing phase 1 clinical trial for its drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Smallcap stock jumps 8% after completing phase 1 clinical trial for its drug - Trade Brains Features","description":"The shares of the generic pharmaceutical products manufacturer gained up to 8 percent after the company reached a significant milestone by completing Phase 1 Clinical Trial for Recombinant Human Albumin (rHA).\u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/smallcap-stock-jumps-8-after-completing-phase-1-clinical-trial-for-its-drug\/","og_locale":"en_US","og_type":"article","og_title":"Smallcap stock jumps 8% after completing phase 1 clinical trial for its drug","og_description":"The shares of the generic pharmaceutical products manufacturer gained up to 8 percent after the company reached a significant milestone by completing Phase 1 Clinical Trial for Recombinant Human Albumin (rHA).\u00a0","og_url":"https:\/\/tradebrains.in\/features\/smallcap-stock-jumps-8-after-completing-phase-1-clinical-trial-for-its-drug\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2024-08-07T09:14:29+00:00","article_modified_time":"2024-08-07T09:55:00+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/smallcap-stock-jumps-8-after-completing-phase-1-clinical-trial-for-its-drug\/","url":"https:\/\/tradebrains.in\/features\/smallcap-stock-jumps-8-after-completing-phase-1-clinical-trial-for-its-drug\/","name":"Smallcap stock jumps 8% after completing phase 1 clinical trial for its drug - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/smallcap-stock-jumps-8-after-completing-phase-1-clinical-trial-for-its-drug\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/smallcap-stock-jumps-8-after-completing-phase-1-clinical-trial-for-its-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","datePublished":"2024-08-07T09:14:29+00:00","dateModified":"2024-08-07T09:55:00+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"The shares of the generic pharmaceutical products manufacturer gained up to 8 percent after the company reached a significant milestone by completing Phase 1 Clinical Trial for Recombinant Human Albumin (rHA).\u00a0","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/smallcap-stock-jumps-8-after-completing-phase-1-clinical-trial-for-its-drug\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/smallcap-stock-jumps-8-after-completing-phase-1-clinical-trial-for-its-drug\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/smallcap-stock-jumps-8-after-completing-phase-1-clinical-trial-for-its-drug\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/smallcap-stock-jumps-8-after-completing-phase-1-clinical-trial-for-its-drug\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Smallcap stock jumps 8% after completing phase 1 clinical trial for its drug"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/130490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=130490"}],"version-history":[{"count":1,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/130490\/revisions"}],"predecessor-version":[{"id":130491,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/130490\/revisions\/130491"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/98971"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=130490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=130490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=130490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}